Additionally, the incidence of MPN-related (JAK2, CALR and MPL) and de novo AML-related (N-RAS, K-RAS and FLT-3) gene mutations is low in typical MDS subsets7, 8, 19, 20. This evidence concerns the gene FLT3 and acute myeloid leukemia.